By acquiring CymaBay, Gilead will gain a drug being developed for primary biliar...
Funding for developing mental health treatments derived from psychedelic drugs c...
In this morning's Pharmalittle roundup, we're reading about Moderna's RSV vaccin...
By one estimate, labor shortages have caused an 11% reduction in dental practice...
As allegations of data mishandling surge, universities and journals are playing ...
Oregon is at the forefront of the push for more scrutiny of deals that have priv...
Innovate UK has awarded £1m grant for a collaborative initiative called AI-VISIO...
The FDA granted breakthrough therapy status for J&J's nipocalimab for pregnant p...
Super Bowl LVIII saw Astellas run awareness for hot flashes and Pfizer touchdown...
The humanised monoclonal antibody DISC-3405 is under investigation in a Phase I ...
RadioMedix and Orano Med’s radioligand therapy AlphaMedix (lead-212-Dotamtate) i...
CSL’s post-MI drug failed to meet its primary endpoint of reducing the risk of m...
Vast quantities of data are only useful to researchers if that data can be easil...
Alys Pharmaceuticals has announced its launch with a R&D pipeline, backed by a $...
The UK MHRA has granted approval for a variation in licence of Pfizer-BioNTech’s...
When a federal official talks about “public-private partnerships,” what they oft...
